Skip to main content
logo
Strata Critical Medical, Inc. (SRTA)
NASDAQ: SRTA · Real-Time Price · USD
4.870
+0.160 (3.40%)
Oct 13, 2025, 1:35 PM EDT - Market open

Strata Critical Medical Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Strata Critical Medical stock has a target of 7.25, which predicts a 48.87% increase from the current stock price of 4.87.

Price Target: $7.25 (+48.87%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$7.25$7.25$7.25$7.25
Change+48.87%+48.87%+48.87%+48.87%

Analyst Ratings

According to 1 stock analyst, the rating for Strata Critical Medical is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingOct '25
Strong Buy1
Buy0
Hold0
Sell0
Strong Sell0
Total1

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Ben Klieve
Lake Street
Lake Street
Strong Buy
Maintains
$6.5 → $7.25
Strong BuyMaintains$6.5 → $7.25+48.87%Sep 17, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
213.54M
from 248.69M
Decreased by -14.14%
Revenue Next Year
273.67M
from 213.54M
Increased by 28.16%
EPS This Year
-0.11
from -0.35
EPS Next Year
-0.01
from -0.11
Fiscal YearFY 2021FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingSep 30, 2021Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
50.53M67.16M146.12M225.18M248.69M213.54M273.67M
Revenue Growth
115.61%32.92%117.58%54.11%10.44%-14.14%28.16%
EPS
-0.93-0.68-0.38-0.76-0.35-0.11-0.01
EPS Growth
-------
Forward PE
-------
No. Analysts
-----55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue202520262027
High273.4M299.2M
Avg213.5M273.7M
Low179.4M245.0M

Revenue Growth

Revenue Growth202520262027
High
9.9%
40.1%
Avg
-14.1%
28.2%
Low
-27.8%
14.7%

EPS Forecast

EPS202520262027
High-0.090.08
Avg-0.11-0.01
Low-0.13-0.10

EPS Growth

EPS Growth202520262027
High--
Avg--
Low--
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.